摘要
目的:了解康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿(BRVO-ME)患者早期最佳矫正视力(BCVA)和黄斑区结构变化情况,评估影响BCVA预后的相关因素。方法:本研究为前瞻性研究。纳入26例BRVO-ME患者,“1+PRN”方案康柏西普(10 mg/mL)0.05 mL玻璃体腔注射,观察1周、1个月、3个月,了解BCVA、黄斑中心凹厚度、黄斑区容积、黄斑区椭圆体带断裂长度变化情况;评估BCVA、黄斑中心凹厚度、黄斑区容积、黄斑区椭圆体带断裂长度与视力预后的相关性。结果:治疗后1个月、3个月BCVA、黄斑中心凹厚度和黄斑区容积均较治疗前有改善(P<0.05);治疗后1周、1个月和3个月椭圆体带断裂长度低于治疗前(P<0.05)。治疗后1周、1月、3月BCVA与治疗前BCVA呈正相关(P<0.0001)。结论:玻璃体腔注射康柏西普治疗BRVO-ME可有效提高视力,改善黄斑水肿,治疗前BCVA是早期视力恢复的预测因素。
Objective:To investigate the best corrected visual acuity(BCVA)and changes of macular structure in patients with branch retinal vein occlusion related macular edema(BRVO-ME)before and after therapy with conbercept,and evaluate related factors affecting the prognosis of BCVA following medication.Methods:Twenty-six patients with BRVO-ME were prospectively enrolled,and underwent intravitreous injection with 0.05mL conbercept(10mg/mL)using“1+PRN”protocol.All eyes were observed at week 1,month 1 and 3 for BCVA,central macula thickness(CMT),macular volume and the rupture length of ellipsoid zone before and after treatment to assess the related factors affecting BCVA after medication.Results:CMT,BCVA and macular volume were greatly improved at month 1 and 3 following therapy(P<0.05),and the rupture length of ellipsoid zone was improved at week 1,month 1 and 3 after treatment(P<0.05).BCVA at week 1,month 1 and 3 after medication was positively correlated with that before therapy(P<0.0001).Conclusion:Intravitreous injection of combercept can improve visual acuity and reduce macular edema in patients with BRVO-ME,and BCVA is the factor in predicting visual prognosis of such patients after medication.
作者
张鹏飞
徐冯媛
梅立新
刘银萍
ZHANG Pengfei;XU Fengyuan;MEI Lixin;LIU Yinping(Department of Ophthalmology,The First Affiliated Hospital of Wannan Medical College,Wuhu 241001,China)
出处
《皖南医学院学报》
CAS
2020年第2期161-164,共4页
Journal of Wannan Medical College
基金
国家自然科学基金项目(81700867)
安徽省自然科学基金项目(1808085MH253)
安徽省高校优秀拔尖人才培育项目(gxgwfx2019034)
弋矶山医院引进人才基金(KY24480297)
弋矶山医院三新项目(Y1928)。
